TrialEBioMedicine2017

Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial.

Mostafa Yakoot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.